
The value of observational causal inference for medical decision making


Wouter van Amsterdam

Department of Data Science and Biostastistics Julius Center for Health Sciences and Primary Care University Medical Center Utrecht, the Netherlands




Medical decisions optimize for patient outcomes under interventions

Need expected outcome under intervention (prediction under intervention)




Medical decisions optimize for patient outcomes under interventions

Need expected outcome under intervention (prediction under intervention) conditional on characteristics



Medical decisions optimize for patient outcomes under interventions

Need expected outcome under intervention (prediction under intervention)




How to estimate treatment effects?


Which generally does not hold in observational data

concurrent vs sequential


Which generally does not hold in observational data

concurrent vs sequential overall survival






$$Y|do(T) \neq Y|T$$



$$Y|do(T) \neq Y|T$$


 $Y|do(T), Z = Y|T, Z$



$$Y|do(T) \neq Y|T$$

$$Y|do(T), Z = Y|T, Z$$

$$Y|do(T) = \sum_{Z} Y|T, Z$$




$$Y|do(T) \neq Y|T$$

 $Y|do(T), Z = Y|T, Z$
 $Y|do(T) \neq \sum_{T} Y|T, Z$


Randomized controlled trials gaurantee unconfoundedness

Thus allow for causal inference



Randomized controlled trials gaurantee unconfoundedness

Thus allow for causal inference



$$Y|do(T) = Y|T$$

Average Treatment Effect (ATE) $\mathbb{E} Y | do(T = A) - Y | do(T = B)$

Average Treatment Effect (ATE)
$$\mathbb{E} Y | do(T = A) - Y | do(T = B)$$

Average Treatment Effect (risk ratio) $\frac{\mathbb{E} Y | do(T = A)}{\mathbb{E} Y | do(T = B)}$


Average Treatment Effect (ATE)
$$\mathbb{E} Y | do(T = A) - Y | do(T = B)$$

Average Treatment Effect (risk ratio) $\frac{\mathbb{E} Y | do(T = A)}{\mathbb{E} Y | do(T = B)}$
Conditional Average Treatment Effect $\mathbb{E} Y | do(T = A), X = x - Y | do(T = B), X = x$


Average Treatment Effect (ATE)
$$\mathbb{E} Y | do(T = A) - Y | do(T = B)$$

Average Treatment Effect (risk ratio) $\frac{\mathbb{E} Y | do(T = A)}{\mathbb{E} Y | do(T = B)}$

RCTs are conducted in non-random samples of the population so transportability assumptions are needed



RCTs are conducted in non-random samples of the population so transportability assumptions are needed




e.g. transportability of risk ratio (RR):

$$RR(pop. = RCT) = RR(pop. = clinical)$$


Trading one unverifiable assumption (unconfoundedness) for another (transportability)

Suspected treatment effect heterogeneity, but RCT too small to measure and lack of equipoise


► RCT establishes average treatment effect




- ► RCT establishes average treatment effect
- ► Treatment effect heterogeneity assumed




- ► RCT establishes average treatment effect
- ► Treatment effect heterogeneity assumed
- ▶ RCT too small to test this heterogeneity (e.g. subgroup tests)




- ► RCT establishes average treatment effect
- ► Treatment effect heterogeneity assumed
- ▶ RCT too small to test this heterogeneity (e.g. subgroup tests)
- Cannot do a new trial because of lack of equipoise



- ► RCT establishes average treatment effect
- ► Treatment effect heterogeneity assumed
- ▶ RCT too small to test this heterogeneity (e.g. subgroup tests)
- Cannot do a new trial because of lack of equipoise
- Need preliminary evidence



- ► RCT establishes average treatment effect
- ► Treatment effect heterogeneity assumed
- ▶ RCT too small to test this heterogeneity (e.g. subgroup tests)
- Cannot do a new trial because of lack of equipoise
- ▶ Need preliminary evidence from observational studies (W. A. C. v. Amsterdam et al. 2022)




Treatments in trials may differ from standard clinical care

Treatments in trials may differ from standard clinical care




Treatments in trials may differ from standard clinical care



▶ Patients don't take medications as prescribed except when monitored in a trial

Treatments in trials may differ from standard clinical care



- ▶ Patients don't take medications as prescribed except when monitored in a trial
- ► Trading one unverifiable assumption (unconfoundedness) for another (consistency)

RCTs solve confounding but have their own limitations




Transportability

RCTs solve confounding but have their own limitations



Transportability




RCTs solve confounding but have their own limitations



Transportability



Consistency




How can observational causal inference help medical decision making?

How observational causal inference can support medical decision making Constant relative treatment effect + varying untreated risk = varying treatment effect

► Transportability assumption needed: most often on relative scale


Constant relative treatment effect + varying untreated risk = varying treatment effect

- ► Transportability assumption needed: most often on *relative scale*
- ▶ Variance in expected outcome under no treatment ($\mathbb{E} Y | do(T = A), X$),




Constant relative treatment effect + varying untreated risk = varying treatment effect

- ► Transportability assumption needed: most often on *relative scale*
- ▶ Variance in expected outcome under no treatment ($\mathbb{E} Y | do(T = A), X$),
 - implies differing effectiveness on absolute probability scale



Constant relative treatment effect + varying untreated risk = varying treatment effect


- ▶ Transportability assumption needed: most often on *relative scale*
- ▶ Variance in expected outcome under no treatment ($\mathbb{E} Y | do(T = A), X$),
 - implies differing effectiveness on absolute probability scale
 - thus varying treatment recommendations




How observational causal inference can support medical decision making Transportability: Need good models of untreated risk

▶ Widely used paradigm (cardiovascular risk, chemotherapy in breast cancer, ...)


- ▶ Widely used paradigm (cardiovascular risk, chemotherapy in breast cancer, ...)
- ▶ Untreated risk is a quantity of the interventional distribution (i.e. causal)




- ▶ Widely used paradigm (cardiovascular risk, chemotherapy in breast cancer, ...)
- ▶ Untreated risk is a quantity of the interventional distribution (i.e. causal)
- Current risk-models: mix of treated / untreated patients (W. v. Amsterdam et al. 2022),



- ▶ Widely used paradigm (cardiovascular risk, chemotherapy in breast cancer, ...)
- Untreated risk is a quantity of the interventional distribution (i.e. causal)
- Current risk-models: mix of treated / untreated patients (W. v. Amsterdam et al. 2022),
- or ungrounded methods (Candido dos Reis et al. 2017; Xu et al. 2021).



- ▶ Widely used paradigm (cardiovascular risk, chemotherapy in breast cancer, ...)
- Untreated risk is a quantity of the interventional distribution (i.e. causal)
- Current risk-models: mix of treated / untreated patients (W. v. Amsterdam et al. 2022),
- or ungrounded methods (Candido dos Reis et al. 2017; Xu et al. 2021).
- ▶ Need better 'causal' methods (Amsterdam et al 2023)



▶ Need large studies for rare events (e.g. COVID-19 vaccinations)

- ▶ Need large studies for rare events (e.g. COVID-19 vaccinations)
- Observational data may improve statistical efficiency of RCTs

- ▶ Need large studies for rare events (e.g. COVID-19 vaccinations)
- Observational data may improve statistical efficiency of RCTs
 - ▶ RCT and observational data share* outcome mechanism

*under transportability assumption

- ▶ Need large studies for rare events (e.g. COVID-19 vaccinations)
- Observational data may improve statistical efficiency of RCTs
 - ▶ RCT and observational data share* outcome mechanism
 - Need less randomized patients when using both data sources (Rosenman et al. 2020; Ilse et al. 2023)

^{*}under transportability assumption

Challenges

- Challenges
 - Unobserved confounding

- Challenges
 - Unobserved confounding
- Opportunities

- Challenges
 - Unobserved confounding
- Opportunities
 - Right population (to be treated)

- Challenges
 - Unobserved confounding
- Opportunities
 - ► Right population (to be treated)
 - ▶ Right treatments (as given in standard clinical care)


- Challenges
 - Unobserved confounding
- Opportunities
 - ► Right population (to be treated)
 - ▶ Right treatments (as given in standard clinical care)
 - ► Bigger data, allows estimating:


- Challenges
 - Unobserved confounding
- Opportunities
 - ► Right population (to be treated)
 - Right treatments (as given in standard clinical care)
 - ► Bigger data, allows estimating:
 - Heterogeneity


- Challenges
 - Unobserved confounding
- Opportunities
 - ► Right population (to be treated)
 - ► Right treatments (as given in standard clinical care)
 - Bigger data, allows estimating:
 - Heterogeneity
 - Rare events

Observational studies


RCT







Observational causal inference and RCTs for medical decision making



Must not abandon RCTs, observational causal inference can be of great value for medical decision making

References

- Amsterdam, W. van et al. (2022). "Decision making in cancer: causal questions require causal answers". In: *submitted*.
- Amsterdam, Wouter A. C. van et al. (Apr. 2022). "Individual treatment effect estimation in the presence of unobserved confounding using proxies: a cohort study in stage III non-small cell lung cancer". en. In: Scientific Reports 12.1. Number: 1 Publisher: Nature Publishing Group, p. 5848. ISSN: 2045-2322. DOI: 10.1038/s41598-022-09775-9. URL: https://www.nature.com/articles/s41598-022-09775-9 (visited on
 - https://www.nature.com/articles/s41598-022-09775-9 (visited on 04/12/2022).
- Amsterdam et al, Wouter A. C. van (Apr. 2023). Conditional average treatment effect estimation with treatment offset models. arXiv:2204.13975 [stat]. URL: http://arxiv.org/abs/2204.13975 (visited on 06/29/2022).
- Candido dos Reis, Francisco J. et al. (Dec. 2017). "An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation". en. In: *Breast Cancer Research* 19.1. 80 citations (Crossref) [2021-08-06], p. 58. ISSN: 1465-542X. DOI: 10/gbhgpq. URL: